HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

JBP 485

has antihepatitis activity

Also Known As:

JBP-485; JBP485; cyclo(4-hydroxyprolyl-seryl)

Networked: 10 relevant articles (3 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - JBP 485: 10
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - JBP 485: 10

Experts

1.	Kaku, Taiichi: 9 articles (10/2015 - 07/2008)
2.	Liu, Kexin: 8 articles (03/2019 - 07/2008)
3.	Wang, Changyuan: 8 articles (03/2019 - 07/2008)
4.	Liu, Qi: 7 articles (09/2013 - 07/2008)
5.	Meng, Qiang: 6 articles (03/2019 - 04/2011)
6.	Sun, Huijun: 6 articles (03/2019 - 07/2008)
7.	Ma, Xiaochi: 5 articles (09/2013 - 06/2009)
8.	Peng, Jinyong: 5 articles (09/2013 - 07/2008)
9.	Wu, Jingjing: 3 articles (03/2019 - 07/2008)
10.	Guo, Xinjin: 3 articles (09/2013 - 07/2012)

Related Diseases

1.	Acute Kidney Injury (Acute Renal Failure) 09/01/2013 - "These results indicated that JBP485 improved acute renal failure by increasing the expression and function of Oat1 and Oat3, and by decreasing overoxidation of the kidney in gentamicin-induced ARF rats. " 11/01/2012 - "The purpose of this study is to investigate whether the effect of cyclo-trans-4-l-hydroxyprolyl-l-serine (JBP485) on acute renal failure (ARF) induced by cisplatin is related to change in expression of renal Oat1, Oat3 and Mrp2 in rats. " 09/01/2013 - "JBP485 improves gentamicin-induced acute renal failure by regulating the expression and function of Oat1 and Oat3 in rats." 11/01/2012 - "Changes in expression of renal Oat1, Oat3 and Mrp2 in cisplatin-induced acute renal failure after treatment of JBP485 in rats."
2.	Inflammation (Inflammations) 10/01/2015 - "Moreover, JBP485 accelerated corneal epithelial wound healing in vivo without inflammation and neovascularization and was found to be effective for the treatment of corneal damage. " 03/01/2019 - "In conclusion, JBP485 alleviated indomethacin-induced intestinal injury through restoring the redox balance, suppressing inflammation, reducing apoptosis, which was further enhanced by Res via upregulation of Pept1 and improvement of bioavailability of JBP485, at least in part."
3.	Corneal Injuries 10/01/2015 - "Moreover, JBP485 accelerated corneal epithelial wound healing in vivo without inflammation and neovascularization and was found to be effective for the treatment of corneal damage. "
4.	Dry Eye Syndromes (Dry Eye Syndrome) 05/21/2015 - "Moreover, JBP485 clinically improved corneal epithelial damage in a mouse dry eye model. "
5.	Hepatitis 06/01/2009 - "We thought it valuable to clarify the anti-hepatitis molecular mechanism of JBP485 to develop a new oral anti-hepatitis drug. " 07/28/2008 - "Evidence has indicated that JBP485 exhibits potent anti-hepatitis activity. " 04/01/2011 - "Cyclo-trans-4-L-hydroxyprolyl-L-serine (JBP485) is a dipeptide with anti-hepatitis activity that has been chemically synthesized. " 03/12/2013 - "Entecavir and JBP485 (a dipeptide) exhibit the antihepatitis activities and it is possible for the two drugs to be coadministered in the treatment of hepatitis. "

Related Drugs and Biologics

1.	Gentamicins (Gentamicin)
2.	Cisplatin (Platino)
3.	Dipeptides
4.	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
5.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
6.	Indomethacin (Indometacin)
7.	entecavir

Related Therapies and Procedures

1.	Aftercare (After-Treatment)